Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
BACKGROUND: The existence of a cross-talk between peritumoral adipocytes and cancer cells has been increasingly investigated. Several studies have shown that these adipocytes protect tumor cells from the effect of anticancer agents.
METHODS: To investigate a potential protective effect of adipocyte-conditioned medium on HER2 positive breast cancer cells exposed to tyrosine kinase inhibitors (TKI) such as lapatinib, we analyzed the sensitivity of HER2 positive breast cancer models in vitro and in vivo on SCID mice in the presence or absence of adipocytes or adipocyte-conditioned medium.
RESULTS: Conditioned medium from differentiated adipocytes reduced the in vitro sensitivity of the HER2+ cell lines BT474 and SKBR3 to TKI. Particularly, conditioned medium abrogated P27 induction in tumor cells by lapatinib but this was observed only when conditioned medium was present during exposure to lapatinib. In addition, resistance was induced with adipocytes derived from murine NIH3T3 or human hMAD cells but not with fibroblasts or preadipocytes. In vivo studies demonstrated that the contact of the tumors with adipose tissue reduced sensitivity to lapatinib. Soluble factors involved in this resistance were found to be thermolabile. Pharmacological modulation of lipolysis in adipocytes during preparation of conditioned media showed that various lipolysis inhibitors abolished the protective effect of conditioned media on tumor cells, suggesting a role for adipocyte lipolysis in the induction of resistance of tumor cells to TKI.
CONCLUSIONS: Overall, our results suggest that contact of tumor cells with proximal adipose tissue induces resistance to anti HER2 small molecule inhibitors through the production of soluble thermolabile factors, and that this effect can be abrogated using lipolysis inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC pharmacology & toxicology - 21(2020), 1 vom: 14. Aug., Seite 61 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Geneste, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0VUA21238F |
|---|
| Anmerkungen: |
Date Completed 02.07.2021 Date Revised 02.07.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s40360-020-00436-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313700427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313700427 | ||
| 003 | DE-627 | ||
| 005 | 20231225151132.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40360-020-00436-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313700427 | ||
| 035 | |a (NLM)32795383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Geneste, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2021 | ||
| 500 | |a Date Revised 02.07.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The existence of a cross-talk between peritumoral adipocytes and cancer cells has been increasingly investigated. Several studies have shown that these adipocytes protect tumor cells from the effect of anticancer agents | ||
| 520 | |a METHODS: To investigate a potential protective effect of adipocyte-conditioned medium on HER2 positive breast cancer cells exposed to tyrosine kinase inhibitors (TKI) such as lapatinib, we analyzed the sensitivity of HER2 positive breast cancer models in vitro and in vivo on SCID mice in the presence or absence of adipocytes or adipocyte-conditioned medium | ||
| 520 | |a RESULTS: Conditioned medium from differentiated adipocytes reduced the in vitro sensitivity of the HER2+ cell lines BT474 and SKBR3 to TKI. Particularly, conditioned medium abrogated P27 induction in tumor cells by lapatinib but this was observed only when conditioned medium was present during exposure to lapatinib. In addition, resistance was induced with adipocytes derived from murine NIH3T3 or human hMAD cells but not with fibroblasts or preadipocytes. In vivo studies demonstrated that the contact of the tumors with adipose tissue reduced sensitivity to lapatinib. Soluble factors involved in this resistance were found to be thermolabile. Pharmacological modulation of lipolysis in adipocytes during preparation of conditioned media showed that various lipolysis inhibitors abolished the protective effect of conditioned media on tumor cells, suggesting a role for adipocyte lipolysis in the induction of resistance of tumor cells to TKI | ||
| 520 | |a CONCLUSIONS: Overall, our results suggest that contact of tumor cells with proximal adipose tissue induces resistance to anti HER2 small molecule inhibitors through the production of soluble thermolabile factors, and that this effect can be abrogated using lipolysis inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adipocytes | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a Lapatinib | |
| 650 | 4 | |a Resistance | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Culture Media, Conditioned |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Lapatinib |2 NLM | |
| 650 | 7 | |a 0VUA21238F |2 NLM | |
| 700 | 1 | |a Duong, M N |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, L |e verfasserin |4 aut | |
| 700 | 1 | |a Conilh, L |e verfasserin |4 aut | |
| 700 | 1 | |a Beaumel, S |e verfasserin |4 aut | |
| 700 | 1 | |a Cleret, A |e verfasserin |4 aut | |
| 700 | 1 | |a Chettab, K |e verfasserin |4 aut | |
| 700 | 1 | |a Lachat, M |e verfasserin |4 aut | |
| 700 | 1 | |a Jordheim, L P |e verfasserin |4 aut | |
| 700 | 1 | |a Matera, E L |e verfasserin |4 aut | |
| 700 | 1 | |a Dumontet, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pharmacology & toxicology |d 2012 |g 21(2020), 1 vom: 14. Aug., Seite 61 |w (DE-627)NLM220735107 |x 2050-6511 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:14 |g month:08 |g pages:61 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40360-020-00436-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 1 |b 14 |c 08 |h 61 | ||